Patent details
EP2225376 Title: RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION
Basic Information
- Publication number:
- EP2225376
- PCT Application Number:
- PCT/DK/2008/000418
- Type:
- European Patent Granted for LU
- Legal Status:
- Lapsed
- Application number:
- EP088576178
- PCT Publication Number:
- WO/2009/071082
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION
- French Title of Invention:
- COMPOSÉS D'ANTAGONISTES D'ARN UTILISÉS POUR MODULER L'EXPRESSION DE PIK3CA
- German Title of Invention:
- RNA-ANTAGONISTVERBINDUNGEN ZUR MODULATION DER PIK3CA-EXPRESSION
- SPC Number:
Dates
- Filing date:
- 26/11/2008
- Grant date:
- 08/01/2014
- EP Publication Date:
- 08/01/2014
- PCT Publication Date:
- 11/06/2009
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 08/09/2010
- EP B1 Publication Date:
- 08/01/2014
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- 26/11/2015
- Expiration date:
- 26/11/2028
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 26/11/2008
- Name:
- Santaris Pharma A/S
- Address:
- Fremtidsvej 3, 2970 Hørsholm, Denmark (DK)
Agent
- Name:
- KIRKPATRICK SA / NV
- From:
- 28/03/2014
- Address:
- AVENUE WOLFERS 32, 1310, LA HULPE, Belgium (BE)
- To:
Inventor
- Name:
- HEDT JÅRN Maj
- Address:
- Denmark (DK)
Priority
- Priority Number:
- 992050 P
- Priority Date:
- 03/12/2007
- Priority Country:
- United States (US)
Classification
- Main IPC Class:
- C12N 15/11;
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|